New cocktail of drugs and radiation takes on tough lung cancer
NCT ID NCT05386888
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested whether adding two newer drugs—GFH018 and toripalimab—to standard chemoradiotherapy could help people with stage III non-small cell lung cancer that cannot be surgically removed. The study enrolled 65 adults and measured how many patients saw their tumors shrink or disappear. The goal is to find a more effective way to control this advanced cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GFH018 (a targeted drug) and toripalimab (an immunotherapy) combined with chemotherapy (paclitaxel, carboplatin, cisplatin, or pemetrexed) and radiation therapy
What this could lead to
If successful, this combination could offer a new treatment option to shrink or control advanced lung cancer that cannot be removed by surgery.
What could go wrong
This is an early phase 2 trial with only 65 participants, so results may not apply to everyone. Adding multiple drugs and radiation raises the risk of serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC, STAGE III are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610000, China